Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance.
Chief Executive Officer Lindy Durrant says: "We are excited to have Sath join us as chief financial officer. His financial acumen and extensive track record of building value in emerging biopharmaceutical companies will benefit Scancell in our next stage of evolution. I look forward to working with him closely as we continue to focus the clinical development of our two lead cancer vaccine assets, SCIB1 and Modi-1, whilst continuing to leverage the potential of our proprietary antibody platform through additional licensing and revenue generating opportunities."
Current stock price: 9.60 pence, down 1.5% on Tuesday
12-month change: down 17%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Scancell Holdings (SCLP)